\
&
Contact us
\
&
Contact us
Published on | 4 years ago
Programmes Digital, Industry & Space Digital EuropeThe publication of the work programmes 2021-2022 of the Digital Europe Programme (DIGITAL) is expected for the upcoming weeks, to be followed shortly after by the first calls for the programme. A kick-off meeting to inform about the content of the programme, its implementation and the support NCP Flanders can give to interested stakeholders is organised jointly by NCP Flanders and the Departement of Economics, Science & Innovation (Departement EWI) on 20 October 2021, 9.00-12.30.
Draft programme
Session 1: Digital Europe and its 2021/2022 Work Programmes (9 to 10 am)
Session 2: Implementation (funding instruments, co-financing and other requirements) (10h15 to 11h15 am)
Session 3: NCP Support (11h30 am to 12h30 pm)
Participation is possible for the entire event or for selected sessions.
Practical information
Targeted public: stakeholders located in Flanders.
Language: The event will be partly held in English and partly in Dutch.
Due to the measures taken following the corona outbreak this meeting will take place in a hybrid format. Places for physical attendance are limited to 20 persons. Online attendance is possible with a computer/laptop and good internet connection.
Registration
A link to register for the event will be available short on the NCP Flanders website.
Any questions can be send to: marie.timmermann@fwo.be.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
